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Abstract
Objective: Although crossover trials enjoy wide use, standards for analysis and reporting have not
been established. We reviewed methodological aspects and quality of reporting in a representative
sample of published crossover trials.
Methods: We searched MEDLINE for December 2000 and identified all randomized crossover
trials. We abstracted data independently, in duplicate, on 14 design criteria, 13 analysis criteria, and
14 criteria assessing the data presentation.
Results: We identified 526 randomized controlled trials, of which 116 were crossover trials. Trials
were drug efficacy (48%), pharmacokinetic (28%), and nonpharmacologic (30%). The median sample
size was 15 (interquartile range 8–38). Most (72%) trials used 2 treatments and had 2 periods (64%).
Few trials reported allocation concealment (17%) or sequence generation (7%). Only 20% of trials
reported a sample size calculation and only 31% of these considered pairing of data in the
calculation. Carry-over issues were addressed in 29% of trial's methods. Most trials reported and
defended a washout period (70%). Almost all trials (93%) tested for treatment effects using paired
data and also presented details on by-group results (95%). Only 29% presented CIs or SE so that
data could be entered into a meta-analysis.
Conclusion: Reports of crossover trials frequently omit important methodological issues in
design, analysis, and presentation. Guidelines for the conduct and reporting of crossover trials
might improve the conduct and reporting of studies using this important trial design.
Introduction
Because they reduce bias associated with imbalance in
known and unknown confounding variables, randomized
clinical trials (RCTs) represent the 'gold standard' for evalu-
ating therapeutic effectiveness.[1] Unlike the parallel group
trial, crossover trials provide each participant with two or
more sequential treatments in a random order usually sep-
arated by a washout period [2]. Within a trial, each partici-
pant is able to act as his or her own control and permits
between and within group comparisons [3,4].
For the study of new and developmental drugs, crossover
studies are extremely popular [4,5], particularly when the
new treatment may only be a slight modification to the
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lation in the responses to the new and old treatments
making the crossover design ideal [6]. Crossover studies
are most appropriate in studies where the effects of the
treatment(s) are short-lived and reversible and are best
suited to trials related to symptomatic but chronic condi-
tions or diseases [3,7]. It is generally agreed that the cross-
over design should not be used when the condition of
interest is unstable and may change regardless of interven-
tions [3]. In spite of criticism [8], however, the crossover
design appears to be used commonly in inappropriate cir-
cumstances [3,9].
Despite their popularity, little is known about the quality
or prevalence of randomized crossover trials. We aimed to
review key methodological issues in the reporting of these
trials in a representative sample of published trials.
Methods
Study cohort
Our study is nested within a larger analysis of RCTs [10]
where we used an extended version of the Cochrane
search strategy (phase 1) to identify all randomized trials
published in December 2000 and indexed on PubMed by
July 2002 [11]. A randomized trial was defined as a pro-
spective study assessing health-care interventions in
human participants who were randomly allocated to
study groups. Abstracts were initially screened to exclude
obvious non-trials, and complete primary reports in the
languages AWC could read (English and French) were
reviewed for all remaining studies.
We defined randomized crossover trials as studies where
an individual receives two or more interventions through
randomization to one of a set of prespecified sequences of
treatments. Appendix 1 displays common characteristics
and features of crossover trials. We included crossover tri-
als of any intervention in any health condition. We
excluded studies examining primarily cost-effectiveness or
diagnostic test properties, as well as studies employing re-
randomization which involves randomization of study
participants into the second stage of a clinical trial [1].
Data collection
Data extraction was conducted by two independent
reviewers (PW and EM) using a standardized pre-piloted
form. We classified trials by journal type, specialty, and
intervention. We also recorded the trial design, study aim,
number of groups (interventions, periods), number of
data collection sites, funding sources, and sample size. If
information about funding sources and number of study
sites was unclear from the trial report, we requested clari-
fication from the trialists. We assessed the reporting of
several important methodological details. We recorded
descriptions of sample size calculations and primary out-
comes. With liberal definitions of adequacy [12], the
reporting of patient preference and methods of random
sequence generation, and allocation concealment were
recorded. We also noted the handling of non-compliers,
carryover, period, and treatment effects. We calculated
descriptive summary statistics both overall and stratified
by study design. We entered the data into an electronic
database such that duplicate entries existed for each study;
when two entries did not match, we reached consensus
through discussion and 3rd party arbitration (BR).
Data analysis
In order to assess inter-rater reliability on inclusion of arti-
cles, we calculated a kappa score which provides a meas-
ure of inter-rater agreement independent of chance [5].
We determined the proportion of crossover trials for each
item reported using simple tabulations and calculated the
exact confidence intervals around a proportion [13].
Results
Results of our literature search
In total, 519 randomized trials published in December
2000 were identified. Of these, 116 or 22% were identi-
fied as crossover studies. Of the 116 publications
included, 2 reported 3 separate trials [14,15], and 7
reported two independent trials within their publication
[16-22]. Therefore, we included a total of 127 randomized
crossover trials. Agreement on the final cohort was excel-
lent (K= 0.94).
Characteristics of the individual trials
In total, 30/127 (24%) trials measured drug pharmacoki-
netics, 36/127 (28%) were non-drug interventions while
almost half, 61/127 (48%) were studies of drug efficacy.
The number of periods ranged between 1 and 6, as six tri-
als reported only on the first period. The median sample
size was 15 (interquartile range: 8–38). Additional File 1
details the reporting characteristics of included studies
stratified by study design (drug efficacy vs. pharmacoki-
netic vs. non-drug intervention). Of all 116 included pub-
lications, one was a letter to the editors [23], one was a
summary of previously conducted research [24], and one
did not contain an abstract [25]. Of the remaining trials,
77/113 (68%) used the term "crossover" in their title or
abstract while 36/113 (33%) did not.
Design of the individual trials
Several important study design characteristics were poorly
reported (Additional File 1). For example, while 92/127
(72%) trials employed an AB/BA design (2 periods, 2
treatments), the study design was unclear in approxi-
mately a quarter of studies, 29/127 (23%). In almost
three-quarters of included studies, carryover effects were
not addressed in the methods section, 90/127 (71%),
although 87/127 (70%) studies either used or explainedPage 2 of 6
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studies it was unclear whether washout was considered. In
the majority of studies, 114/127 (90%), it was not
reported how groups were randomized, while allocation
concealment was reported in less than a fifth of trials, 22/
127 (17%). In total, sample size calculations before the
study were provided in 26/127 (20%) studies. Of these, 8/
26 (31%) reported using a paired data design and, 5/26
(19%, 95% CI: 9–38%) reported post-hoc power calcula-
tions in their results.
Analysis of the individual trials
One hundred and seventeen trials (117/127 (92%) ade-
quately detailed the handling of attrition. Of these, 74/
117 (63%) reported applying an intention-to-treat (ITT)
approach, whereby all patients randomized are included
Flow chart of included studiesigure 1
Flow chart of included studies.
700 excluded:
618 not randomized trials
24 non-English/French 
language
23 trial protocols
19 diagnostic test studies
9 secondary publications
5 economic studies
2 published in November
1542 PubMed citations
842 abstracts
323 excluded:
93 secondary publications
197 not randomized
15 unclear if randomized
7 economic studies
4 protocols/baseline data
3 interim analyses
2 diagnostic test studies
1 paper in Spanish
1 not a real trial
519 randomized trials
403 excluded:
Used a different trial design 
method
116 papers reporting crossover trials
127 crossover trials:
   107 reported one study
   7 reported 2 studies
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described or used in 22/127 (17%) and 17/127 (13%) of
all included studies respectively. While the test for treat-
ment effect was adjusting for co-variates in 4/127 (3%)
studies, 121/127 (95%) studies reported a paired analysis.
Almost all studies 109/127 (86%) did not provide details
regarding patient flow. Only 15/127 (12%) studies ade-
quately described this component in their study design,
with only 3/127 (2%) trials providing the CONSORT
patient flow diagram recommended for parallel group tri-
als.
Patient preference regarding intervention was reported in
10/127 (92%) of the studies. Individual participant data
were presented in 15/127 (12%) studies while results
were displayed graphically in 25/127 (20%). A paired
summary statistic was reported in 118/127 (93%) of stud-
ies. Although the CI or SE was reported in 38/127 (29%)
studies, it was calculable in most of the remaining studies
that had not reported it, 78/89 (88%). Finally, in 79/127
(62%) of the studies, the trialists based their analysis and
conclusions on the differences between groups as
opposed to differences within individuals (i.e. within
groups) – the latter was reported in only 3/127 (2%) stud-
ies. Interestingly, in 45/127 (35%) studies, the authors
interpreted their results based on both differences within
and between groups.
Discussion
We found that important design issues are often under-
reported in randomized crossover trials. Given their pop-
ularity – representing almost a quarter of trials published
in December 2000 [10] – few reported important method-
ological issues such as allocation concealment, issues of
carryover effects, and within-participant effects. Transpar-
ency and interpretation can be improved by creating
standard reporting guidelines for authors and journals
reporting the cross-over trial design. As yet the CONSORT
reporting guidelines [12] have not been extended specifi-
cally for crossover trials.
There are several important strengths and limitations to
be considered in our analysis. Strengths include our rigor-
ous searching of PubMed during the study period, ensur-
ing that adequate time had passed to allow all potential
trials to be filed on the database. We extracted data in
duplicate to reduce abstraction errors and resolved dis-
crepancies by consensus. There are also limitations to con-
sider. We searched only PubMed, the largest and most
accessed database of medical articles. Other databases
may have included additional articles. While every rand-
omized trial published in December 2000 was read and
appraised, it is possible that we missed some trials origi-
nally designed as crossover trials that were reported as par-
allel trials, reporting on only the first or second period of
the trial. The methodological issues that we examined are
a matter of debate. While evidence of bias exists for meth-
odological issues such as blinding, sequence generation
and allocation concealment [26], such evidence is lacking
for other details such as flow diagrams, patient preference,
and importantly, carryover effects. It is possible that if we
had identified other methodological issues, we would
have found different results. However, we developed these
criteria based on studies in which we have participated
and widespread consensus on methodological criteria, as
reported in the CONSORT Statements [27]. Our data
abstraction focused on prespecified criteria. During peer-
review, a reviewer noted the important issue of differing
analysis issues according to whether the main outcome
measure in a trial is continuous, categorical, ordinal or
binary, issues we had not considered. Finally, our analysis
is based on the assumption that the reporting of methods
and results in a published article reflects what was actually
done. It is possible that some authors did conduct the
methodological item, but failed to report it [28].
The crossover design has numerous advantages that inves-
tigators may wish to use for early stage trials. The particu-
lar strength of this design is that the interventions under
investigation are evaluated within the same patients and
so eliminates between-subject variability [4]. Further, this
trial design permits opportunities of head-to-head trials
and patients receiving multiple treatments can express
preferences for or against particular treatments.
However, even when properly applied, crossover trials
may have certain weaknesses. Patients may drop out after
the first intervention period and thus not receive a second
or third treatment. This makes within-subject comparison
impossible [3] and is particularly important if withdrawal
is related to side-effects [2,7]. This further complicates the
concept of intent-to-treat analysis as patients randomized
may complete the first period, but randomization typi-
cally does not occur at the second period. Also, there may
be a residual [5] or carry-over of effect of treatments across
study periods, which could potentially distort the results
obtained during the second treatment or subsequent peri-
ods [7,29], although examples of this are few [30]. Thus,
the observed treatment effects will depend upon the order
in which they were received.
Some have argued against consistent testing for carryover
effects of interventions across periods as carry-over effects
are rare and statistical manipulation after the fact cannot
address the impact of a carry-over effect.[30] Senn, in par-
ticular, has argued for a common sense approach to cross-
over trials, where no carry-over is assumed and thus, not
tested for.[31] He specifically argues that tests for carry-
over are generally underpowered even with an appreciablePage 4 of 6
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out period between periods be sufficient to prevent carry-
over effects. This paper does not aim to solve this issue,
but rather displays the incongruence across crossover tri-
als on the issue of carry-over and other design issues.
Another major potential threat to the validity of the cross-
over design involves the use of inappropriate statistical
analysis [2]. Given that subjects act as their own controls,
the analyses could be based on paired data (using an
unpaired test) [5,6] and the within-subject variability in
outcomes could be considered in sample size calculations
[32]. Essentially, the use of a paired design is much more
efficient than a parallel group design when researchers
expect a high correlation between patients' responses to
the different treatments.
Conclusion
We found large heterogeneity in the reporting of crossover
trials, possibly reflecting a lack of standards within the
field. There is a clear need for minimum standards for
transparent reporting of crossover trials.
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Appendix 1
Features used to assess reporting of methodological
details in published crossover studies
Design
Carryover: concept recognized in the methods section,
credibly was absent and washout was either used or
explained absence.
Allocation: Randomization and concealment methods are
described.
Sample size calculation: methods reported and explained
(prospective versus retrospective, paired vs. unpaired
analysis)
Analysis
Non-Compliers: clear if all participants are included,
excluded, included under intention to treat (ITT) or not
mentioned
Test for carryover effect: Yes formal, Yes informal, No, or
unclear
Test for period effect: Yes formal, yes informal, no, not
clear
Test for treatment effect: paired/unpaired, adjusted/unad-
justed for period effect
Patient preference recorded: yes or no
Presentation
Patient flow: presented as a CONSORT style diagram or
other method
Detail for primary outcome:
• Individual data presented: Yes versus no
Inference
• paired summary statistic: Yes, No but calculable, No
Slant of paper: authors base slant of paper on differences
between groups, within in groups or a combination
Additional material
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